BREAKING
Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 60 minutes ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 2 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 4 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 4 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 5 days ago Earnings Preview: Best Buy (BBY) expected to report lower earnings in Q4 2026 6 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 60 minutes ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 2 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 4 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 4 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 5 days ago Earnings Preview: Best Buy (BBY) expected to report lower earnings in Q4 2026 6 days ago
ADVERTISEMENT
Market News

GW Pharmaceuticals stock jumps 20% on Epidiolex strength

GW Pharmaceuticals (NASDAQ: GWPH) reported third-quarter 2020 financial results before the regular trading hours on Tuesday. The company, which specializes in cannabinoid prescription medicines, reported a 51% spike in Q3 revenue to $137.1 million, surpassing the Wall Street consensus. Net earnings narrowed to 0.03 per share, stronger than the target that analysts had projected. GWPH […]

November 3, 2020 1 min read
“

GW Pharmaceuticals (NASDAQ: GWPH) reported third-quarter 2020 financial results before the regular trading hours on Tuesday. The company, which specializes in cannabinoid prescription medicines, reported a 51% spike in Q3 revenue to $137.1 million, surpassing the Wall Street consensus. Net earnings narrowed to 0.03 per share, stronger than the target that analysts had projected. GWPH […]

· November 3, 2020

GW Pharmaceuticals (NASDAQ: GWPH) reported third-quarter 2020 financial results before the regular trading hours on Tuesday. The company, which specializes in cannabinoid prescription medicines, reported a 51% spike in Q3 revenue to $137.1 million, surpassing the Wall Street consensus. Net earnings narrowed to 0.03 per share, stronger than the target that analysts had projected.

GWPH shares gained 19% during market hours. The stock has increased 4% since the beginning of this year.

GW Pharmacueticals Q3 2020.

Looking forward to listening to management/ analyst comments on Q3 results? Stay tuned here for GW Pharmaceuticals Q3 2020 earnings call transcript

Epidiolex accounted for a lion’s share of the total revenues, contributing $132.6 million in Q3.

CEO Justin Gover said, “We have also now commenced the pivotal Phase 3 program for nabiximols in the treatment of multiple sclerosis spasticity, which provides multiple opportunities for an NDA submission, including as early as next year. Beyond nabiximols, we are advancing several clinical-stage pipeline candidates, including the recent start of a Phase 2 trial in schizophrenia.”

ADVERTISEMENT

____

ADVERTISEMENT

Related Articles